Skip to main content
SpringerLink
Log in

Oral Mucositis Following Cancer Therapy

  • Chapter
  • First Online:
Diseases of the Oral Mucosa

  • 1771 Accesses

Abstract

Oral mucositis (OM) is a common complication of cancer therapy. The clinical presentation varies in severity and dynamics over time based on the cancer therapy modality (radiotherapy to the head and neck, chemotherapy, hematopoietic stem cell transplantation). OM poses a risk for spread of infection locally and systemically, as well as associated with increased consumption of opioids, need for total parenteral nutrition, and increased stay at the hospital.

Numerous scales are available to assess OM. The most commonly used scales combine subjective (symptoms) and objective (signs) components. More specific scales are available for research purposes or for assessment of patient-reported outcomes and quality-of-life.

With the progress in research, several interventions and treatment principles can be recommended for the prevention of OM or for the palliation of its associated pain. The 2020 MASCC/ISOO clinical practice guidelines for the management of OM present these evidence-based interventions.

The emergence of targeted therapy and immunotherapy broadened the clinical profile of OM. This new type of OM has a different pathogenesis and responds to treatment differently than conventional OM.

Thus, after several decades of research about OM, great progress was made for the benefit of improving cancer patient care; however, many more challenges remain.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277–84.

    Article  CAS  PubMed  Google Scholar 

  2. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.

    Article  PubMed  Google Scholar 

  3. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46(6):452–6.

    Article  PubMed  Google Scholar 

  4. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck. 2003;25(12):1057–70.

    Article  PubMed  Google Scholar 

  5. Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE. Oral mucositis induced by anticancer therapies. Curr Oral Health Rep. 2015;2(4):202–11.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009;45(12):1015–20.

    Article  CAS  PubMed  Google Scholar 

  7. Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 1998;25(5):538–51.

    CAS  PubMed  Google Scholar 

  8. Zerbe MB, Parkerson SG, Ortlieb ML, Spitzer T. Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs. 1992;15(3):196–205.

    Article  CAS  PubMed  Google Scholar 

  9. Nishimura N, Nakano K, Ueda K, Kodaira M, Yamada S, Mishima Y, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer. 2012;20(9):2053–9.

    Article  PubMed  Google Scholar 

  10. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998;3(6):446–51.

    Article  CAS  PubMed  Google Scholar 

  11. Ishii E, Yamada SI, Higuchi S, Honjo T, Igarashi H, Kanemitsu S, Ueda K. Oral mucositis and salivary methotrexate concentration in intermediate‐dose methotrexate therapy for children with acute lymphoblastic leukemia. Medical and pediatric oncology. 1989;17(5–6):429–32.

    Google Scholar 

  12. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007;15(5):491–6.

    Article  PubMed  Google Scholar 

  13. Legert KG, Remberger M, Ringden O, Heimdahl A, Dahllof G. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Support Care Cancer. 2014;22(8):2133–40.

    Article  PubMed  Google Scholar 

  14. Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, et al. A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens. Support Care Cancer. 2012;20(5):933–9.

    Article  PubMed  Google Scholar 

  15. Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book. 2013;33(1):e236–e40.

    Article  Google Scholar 

  16. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25(5):1713–39.

    Article  PubMed  Google Scholar 

  17. Shameem R, Lacouture M, Wu S. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Investig. 2015;33(3):70–7.

    Article  CAS  Google Scholar 

  18. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  CAS  PubMed  Google Scholar 

  20. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  21. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer. 2009;115(6):1286–99.

    Article  CAS  PubMed  Google Scholar 

  22. Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, Treister NS. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol. 2015;51(11):1026–33.

    Article  CAS  PubMed  Google Scholar 

  23. Gavrilovic IT, Balagula Y, Rosen AC, Ramaswamy V, Dickler MN, Dunkel IJ, et al. Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist. 2012;17(2):274–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, et al. Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol. 2017;31(10):e464–e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wardill HR, Sonis ST, Blijlevens NMA, Van Sebille YZA, Ciorba MA, Loeffen EAH, et al. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer. 2020;28(11):5059–73.

    Article  CAS  PubMed  Google Scholar 

  26. Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J, European Blood and Marrow Transplantation Mucositis Advisory Group, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy. J Clin Oncol. 2008;26(9):1519–25.

    Article  CAS  PubMed  Google Scholar 

  27. Cattaneo GM, Passoni P, Longobardi B, Slim N, Reni M, Cereda S, et al. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. Radiother Oncol. 2013;108(1):66–71.

    Article  PubMed  Google Scholar 

  28. Shouval R, Kouniavski E, Fein J, Danylesko I, Shem-Tov N, Geva M, et al. Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2019;103(4):402–9.

    Article  CAS  PubMed  Google Scholar 

  29. Tao Z, Gao J, Qian L, Huang Y, Zhou Y, Yang L, et al. Factors associated with acute oral mucosal reaction induced by radiotherapy in head and neck squamous cell carcinoma: a retrospective single-center experience. Medicine. 2017;96(50):e8446.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancers. 2019;11(6):857.

    Article  CAS  PubMed Central  Google Scholar 

  31. Campbell JM, Bateman E, Peters M, Bowen JM, Keefe DM, Stephenson MD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics. 2016;17(4):435–51.

    Article  CAS  PubMed  Google Scholar 

  32. Keshet N, Abu-Tair J, Zaharia B, Abdalla-Aslan R, Aframian DJ, Zadik Y. Superficial oral mucoceles in cancer patient after radiation therapy: an overlooked yet imperative phenomenon. Oral Oncol. 2016;52:e1–2.

    Article  PubMed  Google Scholar 

  33. Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, et al. New Frontiers in the pathobiology and treatment of Cancer regimen-related mucosal injury. Front Pharmacol. 2017;8:354.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016;24(11):4825–30.

    Article  PubMed  Google Scholar 

  35. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–9.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Amy DPB, Shalabi A, Finfter O, Birenzweig Y, Zadik Y. Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature. Immunotherapy. 2020;12(11):777–84.

    Article  CAS  PubMed  Google Scholar 

  37. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.

    Google Scholar 

  38. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017 Available from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

  39. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.

    Google Scholar 

  40. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–13.

    Article  PubMed  Google Scholar 

  41. Berger K, Schopohl D, Bollig A, Strobach D, Rieger C, Rublee D, et al. Burden of oral mucositis: a systematic review and implications for future research. Oncol Res Treat. 2018;41(6):399–405.

    Article  PubMed  Google Scholar 

  42. Singer S, Amdal CD, Hammerlid E, Tomaszewska IM, Castro Silva J, Mehanna H, et al. International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer module, the EORTC QLQ-HN43: Phase IV. Head Neck. 2019;41(6):1725–37.

    Article  PubMed  Google Scholar 

  43. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–20.

    Article  PubMed  Google Scholar 

  44. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423–31.

    Article  PubMed  Google Scholar 

  45. Villa A, Sonis ST. An update on pharmacotherapies in active development for the management of cancer regimen-associated oral mucositis. Expert Opin Pharmacother. 2020;21:1–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA

    Michal Kuten-Shorrer & Sharon Elad

  2. Department of Military Medicine and “Tzameret”, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    Yehuda Zadik

Authors
  1. Michal Kuten-Shorrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yehuda Zadik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sharon Elad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michal Kuten-Shorrer .

Editor information

Editors and Affiliations

  1. Lübeck Institute of Experimental Dermatology (LIED) and Department of Dermatology, University of Lübeck, Lübeck, Germany

    Enno Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kuten-Shorrer, M., Zadik, Y., Elad, S. (2021). Oral Mucositis Following Cancer Therapy. In: Schmidt, E. (eds) Diseases of the Oral Mucosa. Springer, Cham. https://doi.org/10.1007/978-3-030-82804-2_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82804-2_36

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82803-5

  • Online ISBN: 978-3-030-82804-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation